OncoCyte (OCX) Form 3 OncoCyte / Efrem Kamen ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

PURA VIDA INVESTMENTS, LLC

(Last) (First) (Middle)

150 EAST 52ND STREET, SUITE 32001

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/20/2020

3. Issuer Name and Ticker or Trading Symbol
OncoCyte Corp [ OCX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, No Par Value	12,223,953(1)	I	By Pura Vida Investments, LLC(2)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

PURA VIDA INVESTMENTS, LLC

(Last) (First) (Middle)

150 EAST 52ND STREET, SUITE 32001

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

Kamen Efrem

(Last) (First) (Middle)

C/O PURA VIDA INVESTMENTS, LLC

150 EAST 52ND STREET, 32ND FLOOR

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

Explanation of Responses:

1. Shares reported herein are held by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund") and certain separately managed accounts (the "Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager to the Pura Vida Master Fund and the Accounts.

2. The securities reported herein may be deemed beneficially owned by each of: (i) PVI, which is deemed the beneficial owner of shares held by the Pura Vida Master Fund and the Accounts (collectively, the "Client Accounts") in its capacity as investment manager on behalf of itself, and (ii) Efrem Kamen who serves as the Managing Member of PVI. Mr. Kamen exercises voting and dispositive control over the securities and is therefore deemed to be a beneficial owner of securities owned or controlled by PVI. Each of PVI and Mr. Kamen disclaim beneficial ownership of the reported securities held by the Client Accounts, except to the extent of its or his pecuniary interest therein.

	Efrem Kamen /s/ Efrem Kamen	01/28/2021
	Pura Vida Investments LLC /s/ Efrem Kamen, Managing Member	01/28/2021
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.